1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Oman Pharmaceuticals and Healthcare Report Q4 2016

Oman Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 75 pages

Includes 3 FREE quarterly updates

BMI View:

The Oman Ministry of Health's decision to postpone the latest phase of medicine pricereductions highlights the opaque nature of the country's pharmaceutical sector. Over the long term, Oman'spopulation will benefit from more affordable healthcare services as even more medicines are reduced inprice, however the impact on drugmaker's profit margins will continue to come under question.Nonetheless, Oman's evolving demographic and epidemiological profile will act as key drivers of growthwithin the country's pharmaceuticals and healthcare markets over the coming years, supported by anexpanding private sector and the government's ongoing commitment to advancing healthcare.

Headline Expenditure Projections

- Pharmaceuticals: OMR242mn (USD628mn) in 2015 to OMR257mn (USD668mn) in 2016; 6.2% inlocal currency and US dollar terms. Forecast in line with Q316.

- Healthcare: OMR1.15bn (USD3.00bn) in 2015 to OMR1.21bn (USD3.15bn) in 2016; +4.9% in localcurrency and US dollar terms. Forecast in line with Q316.Risk/Reward IndexIn our Q416 Pharmaceutical Risk/Reward Index (RRI) Oman's score of 47.6 out of 100 matches its scorelast quarter, yet moves down one position to 11th place out of 31 countries analysed in the whole MiddleEast and Africa (MEA) region. Regionally, Oman ranks relatively poorly compared to the other Gulf States- only Iraq is positioned lower. Oman has limited longer-term commercial potential due to its smallpopulation, low per capita spending on pharmaceuticals and the fact that the government is responsible forthe bulk of healthcare costs, which will increase the need for cost containment in the coming years.

Table Of Contents

Oman Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Oman 2014-2020) 7
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020) 24
OTC Drug Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Oman 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2014-2020) 29
Industry Risk/Reward Index 30
Middle East and Africa Risk/Reward Index - Q4 2016 30
Oman Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 40
Intellectual Property Issues 41
Pricing Regime 42
Reimbursement Regime 43
Market Overview 44
Healthcare Sector 45
Table: Healthcare Resources (Oman 2010-2015) 47
Table: Healthcare Personnel (Oman 2010-2015) 47
Table: Healthcare Activity (Oman 2010-2015) 48
Research and Development 48
Clinical Trials 49
Epidemiology 50
Competitive Landscape 54
Research-Based Industry 54
Table: Multinational Market Activity 55
Generic Drugmakers 56
Pharmaceutical Distribution 57
Pharmaceutical Retail Sector 57
Company Profile 58
National Pharmaceutical Industries 58
Zynova/Oman Pharmaceutical Products Company 61
Demographic Forecast 64
Table: Population Headline Indicators (Oman 1990-2025) 65
Table: Key Population Ratios (Oman 1990-2025) 65
Table: Urban/Rural Population and Life Expectancy (Oman 1990-2025) 66
Table: Population By Age Group (Oman 1990-2025) 66
Table: Population By Age Group % (Oman 1990-2025) 67
Glossary 69
Methodology 71
Pharmaceutical Expenditure Forecast Model 71
Healthcare Expenditure Forecast Model 71
Notes On Methodology 72
Risk/Reward Index Methodology 73
Index Overview 74
Table: Pharmaceutical Risk/Reward Index Indicators 74
Indicator Weightings 75

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.